ada standards of care 2025 obesity pharmacotherapy glp-1 10 Highlights the of ada standards of care 2025

Mounjaro injection (tirzepatide 15 mg, weekly): around 20% average weight loss over 72 weeks in SURMOUNT-1, the highest figure in the class so far

3 Adverse effects 3.1 Gastrointestinal effects Despite its widespread availability and affordability, metformin is associated with gastrointestinal side effects, including nausea, vomiting, diarrhea, and bloating, affecting around 20% of patients (Sanchez-Rangel and Inzucchi, 2017

Beta-hydroxybutyrate : Beta-hydroxybutyrate is a fundamental test to direct the evaluation of hypoglycemia

That means ensuring youve got the right evidence, and developing a significant number of dossiers